These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24962682)

  • 1. Impact of Medicare Part D on out-of-pocket drug costs and medical use for patients with cancer.
    Kircher SM; Johansen ME; Nimeiri HS; Richardson CR; Davis MM
    Cancer; 2014 Nov; 120(21):3378-84. PubMed ID: 24962682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Medicare Part D for Medicare-age adults with arthritis: prescription use, prescription expenditures, and medical spending from 2005 to 2008.
    Cheng LI; Rascati KL
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1423-9. PubMed ID: 22508663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
    Patel UD; Davis MM
    J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
    Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
    Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicare Part D's effects on elderly patients' drug costs and utilization.
    Ketcham JD; Simon KI
    Am J Manag Care; 2008 Nov; 14(11 Suppl):SP14-22. PubMed ID: 18991476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
    Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP
    Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer.
    Davidoff AJ; Erten M; Shaffer T; Shoemaker JS; Zuckerman IH; Pandya N; Tai MH; Ke X; Stuart B
    Cancer; 2013 Mar; 119(6):1257-65. PubMed ID: 23225522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations.
    Odouard IC; Anderson GF; Alexander GC; Ballreich J
    J Manag Care Spec Pharm; 2024 Mar; 30(3):269-278. PubMed ID: 38140901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of Medicare Part D on health care utilization for non-elderly Medicare recipients with disabilities.
    Nelson RE; Nelson SL; Huttner B; Gundlapalli A
    Disabil Health J; 2014 Jan; 7(1):64-9. PubMed ID: 24411509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicare part D and changes in prescription drug use and cost burden: national estimates for the Medicare population, 2000 to 2007.
    Briesacher BA; Zhao Y; Madden JM; Zhang F; Adams AS; Tjia J; Ross-Degnan D; Gurwitz JH; Soumerai SB
    Med Care; 2011 Sep; 49(9):834-41. PubMed ID: 21544002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of satisfaction and switching costs in Medicare Part D choices.
    Han J; Ko DW; Urmie JM
    Res Social Adm Pharm; 2014; 10(2):398-407. PubMed ID: 23988694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicare Part D research highlights and policy updates, 2013: impact and insights.
    Stubbings J; Lau DT
    Clin Ther; 2013 Apr; 35(4):402-12. PubMed ID: 23541710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in estimated Medicare prescription drug plan costs and affordability for beneficiaries living in different states.
    Davis MM; Patel MS; Halasyamani LK
    J Gen Intern Med; 2007 Feb; 22(2):257-63. PubMed ID: 17356996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Out-of-pocket costs and oral cancer medication discontinuation in the elderly.
    Kaisaeng N; Harpe SE; Carroll NV
    J Manag Care Spec Pharm; 2014 Jul; 20(7):669-75. PubMed ID: 24967520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of Medicare Part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utility.
    Liu FX; Alexander GC; Crawford SY; Pickard AS; Hedeker D; Walton SM
    Health Serv Res; 2011 Aug; 46(4):1104-23. PubMed ID: 21609328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
    Polinski JM; Mohr PE; Johnson L
    Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of an out-of-pocket maximum in Medicare Part D.
    Parasrampuria S; Anderson GF
    Am J Manag Care; 2022 Feb; 28(2):e55-e62. PubMed ID: 35139297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.